Relmada Therapeutics (RLMD) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.72), $0.04 worse than the analyst estimate of ($0.68).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna shares plunge on cancer vaccine data leak
- XTI Aerospace reports preliminary Q3 revenue of $35.3 million
- Independence Gold raises private placement target to $6.25 million
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
